Norah Sadek

Norah Sadek

Auto-generated profile, based on publicly available information

Norah Sadek


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
NSNorah Layla Sadek
Norah Layla Sadek
BCBruno Almeida Costa
Bruno Almeida Costa
KNKarthik Nath
Karthik Nath
SMSham Mailankody
Sham Mailankody

16 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BCBruno Almeida Costa
Bruno Almeida Costa
DDDanai Dima
Danai Dima
TMTomer Mark
Tomer Mark
NSNorah Layla Sadek
Norah Layla Sadek
SIStephen Ijioma
Stephen Ijioma
ARAdriana Rossi
Adriana Rossi
Background/Objectives: Chimeric antigen receptor T-cell therapy (CAR-T) has become a key treatment option for relapsed/refractory multiple myeloma (RRMM), but factors impairing T-cell fitness may diminish efficacy. Our exploratory analysis aimed to evaluate the impact of prior treatment with a selinexor-containing regimen on CAR-T outcomes for RRMM patients. Methods: Data for this retrospective cohort study were sourced from electronic medical records at two US academic centers. Kaplan–Meier estimates assessed duration of response (DOR), progression-free survival (PFS), and overall survival (OS), reported as medians with interquartile ranges (IQRs). Cox proportional hazards regression analyzed factors potentially associated with PFS and OS, reported as hazard ratios (HRs) with 95% confidence intervals (CIs). Results: Among 45 patients exposed to selinexor before undergoing BCMA-directed CAR-T, median therapy line numbers for selinexor use and CAR-T were 7 and 9, respectively, with 24.4% receiving selinexor as part of bridging. At median follow-up of 68 months, median PFS and OS post CAR-T were 8.0 (IQR 3.1–39.5) and 35.9 (IQR 14.2–NR) months, respectively. Overall response rate to CAR-T was 89%, with a median DOR of 8.1 months (IQR 2.9–39.0). In our multivariable model, patients who received a selinexor-based regimen in the line of therapy preceding CAR-T showed a trend toward reduced risk of death (HR = 0.08; 95% CI 0.02–0.46) and/or disease progression (HR = 0.40; 95% CI 0.14–1.09). Conclusions: Prior selinexor exposure does not appear to compromise CAR-T outcomes in heavily pretreated RRMM, suggesting potential T-cell sparing. Our findings warrant larger, prospective studies to determine whether preemptive selinexor treatment can optimize CAR-T efficacy.

31 March 2023
Verified
Other
Open access
GZGao Zhang
Gao Zhang
LWLawrence W. Wu
Lawrence W. Wu
IMIlgen Mender
Ilgen Mender
MBMichal Barzily-Rokni
Michal Barzily-Rokni
MHMarc R. Hammond
Marc R. Hammond
JSJerry W. Shay
Jerry W. Shay
Time-lapse imaging of A375(Fucci2)-CR cells treated with the control.

31 March 2023
Verified
Other
Open access
GZGao Zhang
Gao Zhang
LWLawrence W. Wu
Lawrence W. Wu
IMIlgen Mender
Ilgen Mender
MBMichal Barzily-Rokni
Michal Barzily-Rokni
MHMarc R. Hammond
Marc R. Hammond
JSJerry W. Shay
Jerry W. Shay
Time-lapse imaging of A375(Fucci2)-CR cells treated with 6-thio-dG.

31 March 2023
Verified
Other
Open access
GZGao Zhang
Gao Zhang
LWLawrence W. Wu
Lawrence W. Wu
IMIlgen Mender
Ilgen Mender
MBMichal Barzily-Rokni
Michal Barzily-Rokni
MHMarc R. Hammond
Marc R. Hammond
JSJerry W. Shay
Jerry W. Shay
Time-lapse imaging of A375(Fucci2)-BR cells treated with 6-thio-dG.

31 March 2023
Verified
Other
Open access
GZGao Zhang
Gao Zhang
LWLawrence W. Wu
Lawrence W. Wu
IMIlgen Mender
Ilgen Mender
MBMichal Barzily-Rokni
Michal Barzily-Rokni
MHMarc R. Hammond
Marc R. Hammond
JSJerry W. Shay
Jerry W. Shay